Clinical trials: Secondary Neoplasm
Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder
The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm
This trial aimed to investigate the therapeutic efficacy of ruxolitinib in combination with cytotoxic chemotherapy for post-myeloproliferative neoplasm secondary acute myeloid leukemia.
- Trial name
- NCT03558607
- Testing
- Ruxolitinib
- Where
- 2 sites in South Korea
- Volunteers
- 17 people
- Sponsor
- Seoul National University Hospital
Breast Cancer
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer.
- Trial name
- NCT06206837
- Testing
- vepdegestrant, PF-07220060
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 71 people
- Sponsor
- Pfizer
Nasopharyngeal Carcinoma
Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma
this study is aimed to evaluate the efficacy and safety of the combination of Niraparib and Sintilimab in the treatment of recurrent/metastatic nasopharyngeal carcinoma
- Trial name
- NCT05162872
- Testing
- Niraparib，Sintilimab
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Sun Yat-sen University
Solid Tumor Malignancies, EGFR Positive Solid Tumors
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
This Phase 1, first-in-human (FIH), dose-escalation and dose-expansion study is designed to evaluate the safety, PK, and preliminary anti-tumor activity of VIR-5525 as a monotherapy and in combination with pembrolizumab in…
- Conditions
- Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR
- Trial name
- NCT06960395
- Testing
- VIR-5525, Pembrolizumab
- Where
- 4 sites in United States, Australia
- Volunteers
- 450 people
- Sponsor
- Vir Biotechnology, Inc.
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer
This phase II trial studies how well mirvetuximab soravtansine works as first line in treating patients with triple negative breast cancer.
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03106077
- Testing
- Mirvetuximab Soravtansine
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have recurrent or…
- Trial name
- NCT00022477
- Testing
- BMS-247550
- Where
- 15 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Chicago
Metastatic Nasopharyngeal Carcinoma
Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment
to evaluate the efficacy and safety of toripalimab and capecitabine maintenance therapy in patients with metastatic nasopharyngeal carcinoma (NPC) after first-line gemcitabine/cisplatin combined with toripalimab.
- Trial name
- NCT05484375
- Testing
- Capecitabine plus toripalimab
- Volunteers
- 40 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
SSTR-related Disease, Tumor
Somatostatin Receptor PET/CT in SSTR-Related Disease Patients
To evaluate the potential usefulness of 68Ga/18F-TATE/JR11/LM3 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various SSTR-related disease patients.
- Conditions
- SSTR-related Disease, Tumor, Positron Emission Tomography, Metastasis
- Trial name
- NCT06690957
- Testing
- 68Ga/18F-TATE/JR11/LM3
- Where
- 3 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Squamous Cell Carcinoma, Head And Neck
A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma
Given that up-regulation of the Wnt pathway has been identified as having a significant role in carcinogenesis in advanced head and neck squamous cell carcinoma, the investigator believes that inhibition of Porcupine via WNT974…
- Trial name
- NCT02649530
- Testing
- WNT974
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center
Solid Cancers
A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies
The study consists of two stages. In Stage 1, maximum tolerated dose (MTD) will be determined. In Stage 2, additional patients will be treated at the MTD of GDC-0152.
- Trial name
- NCT00977067
- Testing
- GDC-0152
- Volunteers
- 40 people
- Sponsor
- Genentech, Inc.
Metastatic Cancer, Radiation Toxicity
Melatonin and Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as melatonin may make tumor cells more sensitive to radiation therapy and may protect normal cells from the side effects of radiation therapy.
- Conditions
- Metastatic Cancer, Radiation Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00031967
- Testing
- therapeutic melatonin, radiation therapy
- Where
- 234 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer Metastatic Castration-Resistant
A Study of KMV002 in Patients With mAPMR Prostate Cancer
This is a first-in-human (FIH) open-label, multicenter, dose-escalation and dose-expansion Phase I study of KMV002 in metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer patients.
- Trial name
- NCT07866300
- Testing
- KMV002
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Chimivac INC
Lung Cancer
Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00114192
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Virginia
Lung Cancer, Lung Cancer Metastatic
Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors
The feasibility of a RF ablation catheter to bronchoscopically ablate lung tumors, will be evaluated in patients already scheduled for surgical resection.
- Conditions
- Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell
- Trial name
- NCT03272971
- Testing
- Radio-frequency Ablation
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Broncus Medical Inc
Breast Cancer
Extended Treatment in Metastatic Breast Cancer With Eribulin
Decision-making for treatment of metastatic breast cancer after the second line of chemotherapy was limited by the lack of established predictive factors of benefit for further chemotherapy regimens.
- Trial name
- EXTER (NCT02769364)
- Where
- 21 sites in Spain
- Volunteers
- 45 people
- Sponsor
- Eisai Limited
Breast Cancer, Colorectal Cancer
Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)
The aim of the study is to determine blood concentration evolution of capecitabine and its active metabolites, in elderly patient 75 years and more.
- Trial name
- capagec (NCT00812864)
- Testing
- Capecitabine
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Limoges
Peritoneal Cancer, Peritoneal Metastases
The PIPAC-OPC7 Study: The Use of PET/CT Scans as a Method of Evaluation in Patients Treated With PIPAC, a Pilot Study.
The pilot study will investigate the use of repeated FDG-PET/CT scans in 16 patients with peritoneal metastasis originating from abdominal cancers treated with Pressurized Intraperitoneal Aerosol Chemotherapy.
- Conditions
- Peritoneal Cancer, Peritoneal Metastases, Peritoneal Carcinomatosis, Abdominal Cancer
- Trial name
- NCT06144853
- Testing
- scan
- Where
- Denmark
- Volunteers
- 34 people
- Sponsor
- Odense University Hospital
Metastatic Renal Cell Carcinoma
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
Primary objective: to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of SUTENT®.
- Trial name
- NCT00684645
- Testing
- SUTENT
- Where
- 20 sites in Czechia
- Volunteers
- 186 people
- Sponsor
- Pfizer
Advanced Gastric Cancer, Paclitaxel Polymeric Micelles for Injection
A Single-arm, Single-center Phase II Clinical Study on the Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Combined With Fruquintinib Capsules in the Second-line Treatment of Patients With Advanced Gastric Cancer
This study is a single-arm, open, phase II clinical trial aimed at evaluating the anti-tumor efficacy and safety of paclitaxel polymeric micelles for injection combined with furquintinib as second-line treatment for advanced…
- Conditions
- Advanced Gastric Cancer, Paclitaxel Polymeric Micelles for Injection, Fruquintinib Capsules
- Trial name
- NCT06706895
- Testing
- Paclitaxel Polymeric Micelles for Injection combined with Fruquintinib Capsules
- Volunteers
- 21 people
- Sponsor
- Shanghai Zhongshan Hospital
Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
This study is being conducted to evaluate the safety and efficacy of the combination of pemetrexed and zanubrutinib (called induction therapy) followed by zanubrutinib treatment alone (also called maintenance therapy) in people…
- Conditions
- Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT05681195
- Testing
- Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Baptist Health South Florida